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Abstract
The mono-6-deoxy-6-azides of 2,6-di-O-methyl-β-cyclodextrin (DIMEB) and randomly methylated-β-cyclodextrin (RAMEB) were
conjugated to propargylated hydroxyethyl starch (HES) by Cu+-catalysed [2 + 3] cycloaddition. The resulting water soluble poly-
mers showed lower critical solution temperatures (LCST) at 52.5 °C (DIMEB-HES) and 84.5 °C (RAMEB-HES), respectively.
LCST phase separations could be completely avoided by the introduction of a small amount of carboxylate groups at the HES back-
bone. The methylated CDs conjugated to the HES backbone exhibited significantly lower cytotoxicities than the corresponding
monomeric CD derivatives. Since the binding potentials of these CD conjugates were very high, they are promising candidates for
new oral dosage forms of anaesthetic actives.
Introduction
Cyclodextrins (CDs), α(1→4) linked cyclic oligomers of anhy-
droglucose, are produced nowadays in industrial scale [1]. CDs
are able to complex hydrophobic or amphiphilic guest mole-
cules in aqueous phase [2]. β-CD, the seven membered ring
forms inclusion compounds with derivatives of benzene,
naphthalene, adamantane, and many other moieties of similar
sizes [3]. Applications of β-CD as complexing agents are
limited because of low aqueous solubilities of β-CD and its
complexes. Furthermore, the toxic potential of β-CD is known
for a long time. β-CD can cause haemolysis due to extraction of
cholesterol from cell walls [4,5]. Also the parenteral applica-
tion of high doses of β-CD can cause kidney diseases [6,7].
Consequently, pharmaceutical applications of β-CD are
restricted to oral dosage forms, such as piroxicam β-CD [8-10].
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Scheme 1: Synthesis of azido functionalized DIMEB 1a. a) Ba(OH)2·8H2O/BaO/Me2SO4
Toxicity of β-CD can be minimized by derivatisation [11,12].
Both, hydroxypropyl-β-CD (HP-β-CD) and sulfobutyl-β-CD are
less toxic than β-CD, but they are less defined due to a statis-
tical substitution pattern [13]. HP-β-CD often shows a reduced
binding potential compared to β-CD [2,14]. On the other hand,
methylation of β-CD leads to excellent solubilities in water and
high binding potentials, but causes even higher toxicity
compared to native β-CD. Among the methyl derivatives of
β-CD the heptakis-2,6-di-O-methyl derivative, abbreviated as
DIMEB [15], showed very high binding potentials [16] and was
already discussed by Szejli as a very promising candidate for
parenteral drug delivery [17], but it was placed back because of
its high toxicity [5,18,19]. Therefore our aim was to conjugate
DIMEB for the first time to a polymeric backbone, which
should hinder cellular uptake. CD polymers are known to have
a much lower toxic potential compared to CD monomers [20].
Native β-CD was already conjugated by esterification [21],
reductive amination [22-25], amide coupling [26,27] and [2 + 3]
cycloadditions [28] to both biogenic and synthetic polymers.
Conjugation of CDs to polysaccharides like chitosane [29], algi-
nate [24] and dextrane [28] is advantageous for the design of
drug delivery systems because of the low toxicities and
biodegradabilities of those polymers. Among the various
coupling reactions, the [2 + 3] cycloaddition of alkynes and
azides, the so-called Huisgen reaction [30] and its Cu+-
catalyzed version, called click reaction [31,32], is of special
interest because this coupling proceeds rapidly and specific in
aqueous media and tolerates many functional groups. Mono-6-
azido-6-deoxy-β-CD was already coupled by the click reaction
to propargylated dextrane by Nielsen et al. [28]. We intended to
conjugate the corresponding methylated mono-azido-β-CD
derivatives to propargylated hydroxyethyl starch (HES). Advan-
tages of HES are its very high aqueous solubility paired with
good biocompatibility and its very low allergenic potential [33].
HES is in use for a long time for many parenteral applications,
such as plasma expanders [34]. Its rate of bio-degradation
increases with decreasing the degree of substitution (MS) of the
hydroxyethyl side groups. Nowadays, HES with a molecular
weight of Mw = 130 kDa and MS <0.5 is preferred [35]. In the
following, we describe the conjugation of azido-functionalized
methylated β-CD derivatives to propargylated HES, the evalua-
tion of the toxicity of these new polymers and first binding
studies for the hydrophobic anaesthetic ingredients sevoflurane
and midazolam. Sevoflurane, currently applied as an inhalation
anaesthetic [36], could be solubilized in water to allow further
use in oral or parenteral dosage forms as an analgesic drug.
Also the uptake of midazolam could be improved by complexa-
tion in CD derivatives [37,38].
Results and Discussion
Cyclodextrin polymers were synthesized by copper-catalyzed
[2 + 3] cycloaddition of methylated derivatives of mono-6-
azido-6-deoxy-β-CD (β-CD-N3) and propargylated hydroxy-
ethyl starch (HES). Furthermore, a partially oxidized propargy-
lated HES was employed as hydrophilic polymer backbone.
The methylated β-CD-N3 was synthesized in a 3 step procedure
starting from β-CD which was first converted via the 6-O-tosy-
late to β-CD-N3 following the procedures of Hocquelet et al.
who also described the permethylated β-CD-N3 [39]. Further-
more, we headed for the regioselective 2,6-dimethylated prod-
uct. Therefore β-CD-N3 was carefully methylated by dimethyl
sulfate and a mixture of Ba(OH)2·8H2O and BaO as the base
following the procedure of Szejtli et al. published for the
methylation of native β-CD [15] (Scheme 1).
The product 1a showed a quite narrow distribution of methyl
substituents as revealed by the ESIMS showing signals corres-
ponding to β-CD-N3 derivatives with 14 to 18 methyl groups
(Figure 1). From the average number of the molecular weight
obtained from the ESIMS, Mn = 1383.6 g mol−1 a degree of
substitution of methyl groups DSCD(methyl) = 2.2 per glucose
unit was derived.
This value of DSCD(methyl) was confirmed by the well
resolved 1H NMR spectrum (Figure 2). After setting the inte-
gral of the H-3 proton to 1 the signals in the range between 4.8
and 5.4 ppm integrated to a value of 12.18 protons. Taking into
account the 7 anomeric protons 5.18 OH protons per CD are
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Scheme 2: Synthesis of propargylated HES 2.
Figure 1: ESI mass spectrum of azido functionalized DIMEB 1a.
left, which is equivalent to a DSCD(methyl) = 2.2. The signals at
3.66 ppm and 3.43 ppm were assigned to the methyl groups in
O-2 and O-6 position, respectively [40]. Nearly no signal was
found corresponding to methyl groups in O-3 position. If the
according methylation was instead performed with NaOH as the
base it proceeded much faster and with a high chance of over-
methylation. Careful control of the reaction time lead to
another product 1b with a similar degree of methylation
DSCD(methyl) = 2.3, but a much higher structural hetero-
geneity as demonstrated by the 1H NMR spectrum (Figure 3s,
Supporting Information File 2) which was much less resolved
than the spectrum of 1a (Figure 2a). Methylations employing
NaOH as the base [41] are known to be less regioselective than
those using barium hydroxide [41].
A commercial HES with an average molar mass Mw = 130 kDa
and a molar degree of substitution of MS(hydroxyethyl) = 0.4
was functionalized by reaction with propargyl glycidyl ether in
water (Scheme 2) in analogy to a procedure published by
Nielsen et al. for the synthesis of β-CD-dextran polymers [28].
The degree of substitution of HES with propargyl groups,
DSHES(propg), was determined by 1H NMR spectroscopy from
the integral of the methylene protons of the propargyl groups
H-12 at 4.75 ppm relative to the ones of the anomeric proton
H-01 of starch at around 5.5 ppm (Figure 2b). Surprisingly
DSHES(propg) increased with decreasing concentration of the
base NaOH. Only a moderate DSHES(propg) = 0.4 could be
reached in 0.75 M NaOH, while a higher DSHES(propg) = 0.65
was accomplished in 0.1 M NaOH after 2 d reaction time. The
decreasing yield was rationalized by the increasing consump-
tion of propargyl glycidyl ether by hydrolysis with increasing
OH− concentration. On the other hand, due to the low pKa ≈ 12
of polyglucanes, deprotonation still takes place at very low
concentrations of OH− [42,43]. Indeed the modification of HES
seems to take place exclusively at the unsubstituted glucose
units, because the signal of the anomeric proton H-01 of the
unsubstituted glucose unit at 5.4 ppm [44] of HES (see
Figure 1s, Supporting Information File 2) had nearly completely
vanished in the product spectrum shown in Figure 2b. The HES
derivative with DSHES(propg) = 0.65, 2, was selected for the
further coupling to azido-CD derivatives. Also a hydroxyethyl
starch, where the CH2OH groups had been partially oxidized by
TEMPO to carboxylate groups [45,46], was functionalized by
reaction with glycidyl propargyl ether leading to a highly water
soluble polymer 3 with DSHES(propargyl) = 0.55.
Coupling of the CD azides 1a and 1b to the propargylated HES
was performed by Cu+-catalyzed [2 + 3] cycloaddition, the
so-called click reaction, leading to the corresponding triazol
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Figure 2: 1H NMR spectra of a) 1a, b) 2, and c) 5a.
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Scheme 3: Synthesis of 5a by [2 + 3] cycloadditon, a) CuSO4, ascorbate, 50 °C, 48 h.
Table 1: Compositions, yields, and LCST of methylated CD-HES conjugates synthesized by [2 + 3] cycloaddition.
Name DSCD(Me) DSHES(CD) DSHES(COONa) Yield [%] MCD [Da] LCST [°C]
4 0 0.1 0 70 3410 no
5a 2.2 0.4 0 90 1985 52.5
5b 2.3 0.35 0 94 2054 84.5
6 2.2 0.45 0.27 95 1940 no
groups (Scheme 3). The standard protocol, introduced by
Sharpless [31], using CuSO4 plus ascorbic acid as the catalyst
already gave rise to high coupling yields. The resulting conju-
gates of HES and methylated CDs were isolated by ultrafiltra-
tion in nearly quantitative yields (Table 1). Nearly all propargyl
groups at the HES detectable by the 1H NMR signal H-12 at
4.26 pm were converted to triazole groups (1H NMR signal
H-14 at 8.03 ppm), shown in Figure 2c. The corresponding IR
spectra (Figure 5s, Supporting Information File 2) revealed that
the excess of azido-CD had been completely removed by the
ultrafiltration step since the band of the azido group at
2102 cm−1 was not detectable anymore in the product. The
degree of substitution of HES by CD, DSHES(CD), was deter-
mined from the ratio of the 1H NMR signals of H-14 at
8.06 ppm (0.38 protons) and of the anomeric proton H-01 of
starch at 5.66 ppm.
All of the methylated CD-HES conjugates, listed in Table 1,
were clearly soluble in water at ambient conditions but most of
them precipitated at elevated temperatures. This so-called lower
critical solution temperature is typical for alkylated neutral
polysaccharides and attributed to increasing hydrophobic inter-
actions with increasing temperatures [47-49]. Only the CD-HES
conjugate 6 did not show any precipitation below 100 °C which
was attributed to the much higher hydrophilicity of the anionic
carboxylate groups at the HES backbone compared to unmodi-
fied HES.
Cytotoxicity assays
The effect of the CD polymer 5a on the cell viability was
assessed using the ATP-based CellTiter-Glo® assay [50] on the
human colon tumor cell line Caco-2. A first series of tests was
performed in the relevant concentration range, i.e., 10× lower
and up to about 10× above the clinically relevant concentration,
namely 0.25 till 25 mg/mL of the polymer 5a in the medium for
2 h and 24 h incubation times, respectively (Figure 3a,b). For
comparison, the same viability test was carried out with DIMEB
(Figure 3c,d).
According to DIN EN ISO 10993-5 [51], a more than 30%
deviation of measurement values of treated cells compared to
the untreated control was defined as cytotoxic. After treatment
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Figure 3: Viabilities of Caco-2 cells incubated with a) 5a after 2 h, b) 5a after 24 h, c) DIMEB after 2 h, d) DIMEB after 24 h, in serum (black), in basal
medium (grey).
of the Caco-2 cell line, not any cytotoxic effect could be
detected for all of the tested concentrations of 5a after 2 h of
incubation, while DIMEB was already highly toxic at
25 mg/mL. After 24 h of incubation, 5a also showed a rather
weak toxicity, while DIMEB was already highly toxic at the
clinically relevant concentration (see Figure 3). The effect of
the culture medium was negligible.
Complexation of anaesthetic drugs by CD
polymers
The complexation of the anaesthetic drug sevoflurane (shown in
Scheme 4) by the methylated CDs and CD polymers was quan-
tified by measurement of the vapor pressure of the sevoflurane
by gas chromatography as a function of the CD concentration as
already described previously [14,52]. The respective occupan-
cies of the hosts occupancies (the molar ratios of complexed
guest vs. host) are listed in Table 2. While native β-CD shows
only a weak affinity to sevoflurane, the methylated CDs Scheme 4: Structures of a) midazolam and b) sevoflurane.
RAMEB and especially DIMEB show satisfactory occupancies.
Methylation increases the hydrophobicity of the CD cavity and
therefore improves the compatibility with the hydrophobic
guest sevoflurane. Surprisingly, the completely methylated
β-CD TRIMEB had a much lower binding potential to sevoflu-
rane than all other CD derivatives. Low binding affinities of
TRIMEB are also known towards other guest molecules, such
as tert-butyl benzoate and adamantane-1-carboxylate, and had
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been rationalized by the lack of intramolecular hydrogen bonds
which would otherwise rigidify the CD scaffold [16]. The occu-
pancies of the HES polymers (see Table 2) also increased with
increasing degree of methylation, DSCD(CH3) similar to the
monomeric CDs. The anionic polymer 6 showed a somewhat
smaller binding potential.
Table 2: Occupancies for methylated CDs and CD polymers.
Host DSCD(CH3) Sevoflurane Midazolam
[mol %] [mol %]
β-CD 0 32 2
RAMEB 1.8 47 6
DIMEB 2.0 69 18
TRIMEB 3.0 8 <1
4 0 34 <3
5a 2.2 67 24
5b 2.3 67 26
6 2.2 47 19
The complexation of the anaesthetic drug midazolam (shown in
Scheme 4) by the methylated CDs and CD polymers was quan-
tified by the phase solubility method [53,54]. Solubility of
midazolam was measured by UV spectroscopy as the function
of the concentration of the CD derivative. The resulting occu-
pancies are listed in Table 2. The value for native β-CD was
quite low and in accordance with results previously obtained by
1H NMR spectroscopy [55]. Again DIMEB showed the highest
value. Occupancies of the polymers were in the same order of
magnitude or even higher than for the respective CD monomers
(Table 2).
Conclusion
The attachment of DIMEB to a polymer backbone by the click-
reaction is a very efficient way to synthesise polymeric hosts
with both low toxicity and excellent binding potential. The
conjugate of DIMEB and HES 5a is regarded as a good candi-
date for oral or parenteral delivery of hydrophobic drugs.
Experimental
Complexation of sevoflurane. The vapor pressure of sevoflu-
rane was determined by head space gas chromatography with a
Shimadzu GC-17A GC equipped with a head space unit from
Shimadzu, Japan. Vials of 5 mL volume were used, the ratio
between gas (V = 3.2 mL) and aqueous (V = 1.8 mL) phase was
f = 1.77. Occupancies were calculated from the GC data as
described previously [56].
Complexation of midazolam. An excess amount of mida-
zolam was added to aqueous solutions containing various
concentrations of CD polymers and stirred for 24 h at 25 °C.
After equilibration, aliquots of the suspension were filtered
through a 0.20 μm membrane cellulose filter, suitably diluted
and analyzed using UV spectroscopy. The concentration of
midazolam in each solution was determined by measuring its
absorbance at 240 nm (ε = 21,240 M−1cm−1). The intrinsic
absorption of each CD polymer was taken into account.
Cell viability was determined using CellTiter-Glo® assay
(Promega, #G7571) and Caco-2 colon carcinoma cells (DSMZ
#ACC-169; passage 9-17). Cells were cultured as described by
the supplier, seeded with 5 × 103 cells per well in 96-well plates
and tests carried out at about 80% cell confluency (~3–4 days).
The assay results in cell lysis and generation of a luminescent
signal proportional to the amount of ATP present, which is
directly proportional to the number of cells in culture. The lumi-
nescence signal was measured in a plate reader (infinite M200,
TECAN, Männedorf, Swizerland). 5a and DIMEB were each
solved in standard basal medium (MEM) or human serum and
cells were treated for 2 h and 24 h with the above-mentioned
concentrations. For viability assessment, the test substances
were removed by washing with PBS buffer (Sigma®), the cells
in each well were overlaid with 100 µL of basal medium and
100 μL of CellTiter-Glo® reagent and luminescence was
measured after 2 min of shaking and 10 min incubation at room
temperature in the TECAN plate reader. All results presented
are based on at least three independent biological tests. Statis-
tical significance was determined by analysis of variance and
p < 0.05.
Materials: Hydroxyethyl starch (HES) with an average molar
mass (Mw) of 130 kDa and a molar substitution of 0.4 was
kindly provided by Fresenius Kabi, Friedberg, Germany (batch
no: 17120211). β-CD was obtained from Wacker Chemie
GmbH, München, Germany. HES and CD were used after
drying overnight at 70 °C under reduced pressure. All other
reagents and solvents were purchased from commercial
suppliers and used as received. Mono-6-deoxy-6-azido-β-CD
was synthesized according to a literature protocol [57]. All
complexation studies were performed in saline HEPES-buffer
solution (pH 7.4) with a NaCl concentration of 0.9 wt %.
Mono-6-deoxy-6-azido-heptakis(2,6-di-O-methyl)-β-
cyclodextrin (1a): 3.0 g (2.59 mmol) mono-(6-deoxy-6-azido)-
β-CD was dissolved in 150 mL DMF/DMSO 1:1 (v/v) under N2
and a mixture of 26 g (168 mmol) BaO and 26 g Ba(OH)2
(153 mmol) was added in small portions within 10 min under
stirring. The mixture was cooled to 0 °C and 30 mL (0.32 mol)
dimethyl sulfate was added over a period of 1 h under intensive
stirring keeping the internal temperature below 5 °C. Stirring
was continued for 4 d at rt. Then the mixture was warmed up to
85 °C for 30 min. After cooling to rt, excess dimethyl sulfate
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was decomposed by addition of 50 mL of 25 wt % aqueous
ammonia. The mixture was stirred for 16 h and neutralized by
addition of conc. HCl. Then 180 mL chloroform was added,
filtered and the precipitate was washed with further 80 mL chlo-
roform. The filtrate was concentrated to dryness in vacuum,
dissolved in water, purified by nanofiltration with water against
a polyethersulfone membrane (cut-off: 1 kDa) and lyophilized.
Yield: 2.5 g (1.86 mmol, 72%); DS: 2.2; 1H NMR (400 MHz,
CDCl3) δ 5.25–4.94 (m, 12H, H-1/1‘, OH-3/3‘), 3.94–3.92 (m,
7H, H-3/3‘), 3.75–3.40 (m, 74H, H-4/4‘, H-5/5‘, H-6/6’a/6’b,
H-7/7‘, H-8, H-9), 3.29–3.21 (m, 7H, H-2/2‘); 13C NMR (100
MHz, CDCl3) δ 101.3 (C-1), 83.5 (C-4), 82.0 (C-2), 73.2 (C-3),
70.8 (C-6a/b), 70.3 (C-5), 61.7 - 58.2 (C-7, C-8, C-9), 51.8
(C-6’a/b); MS (m/z): [M + Na+] 1364.63, C55H95N3O34, (m/z):
[M + Na+ + CH3] 1378.02, C56H97N3O34, (m/z): [M + Na+ +
2CH3] 1392.64, C57H99N3O34, most intense peak (m/z): [M +
Na+ + 3CH3] 1406.29, C58H101N3O34, (m/z): [M + Na+ +
4CH3] 1420.20, C59H103N3O34; IR  (cm−1): 3412 (OH), 2930
(CH), 2102 (N3), 1453 (CH), 1361 (OH).
(3-Propargyloxy-2-hydroxypropyl)-hydroxyethyl starch (2):
3.412 g (18.98 mmol) HES was dissolved in 40 mL 0.1 M
NaOH and 1.8 mL (16.70 mmol) glycidyl propargyl ether were
added. The temperature was increased to 35 °C and the solution
was stirred. After 24 h further 1.8 mL (16.70 mmol) glycidyl
propargyl ether were added and stirred for another 16 h. The
product was precipitated in 500 mL 2-propanol, filtered and
washed with 200 mL 2-propanol. The product was purified by
ultrafiltration with water against a polyethersulfone membrane
(cut-off: 5 kDa) and freeze-dried.
Yield: 3.61 g (14.97 mmol, 79%); DS: 0.65; 1H NMR (400
MHz, DMSO-d6/D2O) δ 5.68–5.38 (m, 1H, H-01/01‘), 4.27 (s,
1.30H, H-12‘), 4.03–3.45 (m, 10H, H-02/02‘, H-03/03‘, H-04/
04‘, H-05/05‘, H-06/06‘, H-07/07‘, H-08/08,H-9‘, H-10‘,
H-11‘, H-14‘); IR  (cm−1): 3400.25 (OH), 2925.80 (CH),
2113.83 (-C≡C), 1456.15 (CH), 1365.50 (OH).
Conjugate of DIMEB and HES 5a: Under an atmosphere of
N2 1.6 g (1.19 mmol) 1a was dissolved in 40 mL of degassed
DMSO/H2O 1:1 (v/v) and 600 mg (2.4 mmol) 2 and 334 µL
(119 µmol) of a solution of sodium ascorbate in water
(70 mg/mL) were added. After reaching 50 °C, 211 µL
(59 µmol) of a solution of CuSO4·5H2O in water (70 mg/mL)
was added. The solution was stirred for 48 h and purified by
ultrafiltration with water against a polyethersulfone membrane
(cut-off: 5 kDa) and freeze-dried.
Yield: 1.67 g (2.15 mmol, 90%); DS: 0.4; 1H NMR: (400 MHz,
D2O) δ 8.03 (s, 0.4H, H-14‘), 5.58 (m, 1H, H-01/01‘), 5.14 (m,
2.8H, H-1/1‘), 3.86–3.07 (m, 45H, H-02/02‘–H-08/08‘, H2/
2‘–H-7/7‘, H8, H9‘–H12‘); IR  (cm−1): 3400.25 (OH),
2925.80 (CH), 1456.15 (CH), 1365.50 (OH).
Supporting Information
Supporting Information File 1
General methods and experimental procedures for
compounds 1b, 3, 4, 5b and for the oxidation of HES.
[http://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-10-325-S1.pdf]
Supporting Information File 2
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